Sunday, September 8, 2013

FAU Charles E. Schmidt College of Medicine Professor is “Fries Prize for Improving Health” Awardee for 2013



   Charles H. Hennekens, M.D., Dr.P.H. Honored for His Major Contributions World-wide
in Reducing Premature Death and Disability from Heart Attacks and Strokes

BOCA RATON, Fla. (July XX, 2013) —Charles H.  Hennekens, M.D., Dr.P.H., the first Sir Richard Doll professor and senior academic advisor to the dean in the Charles E. Schmidt College of Medicine at Florida Atlantic University will receive the prestigious 2013 “Fries Prize for Improving Health.” The Fries Prize for Improving Health was established in 1992 by the James F. and Sarah T. Fries Foundation to recognize individuals who have done the most to improve health, as judged by an expert and prestigious selection jury. The award will be presented on October 7, 2013 at the Centers for Disease Control and Prevention (CDC) in Atlanta, Georgia. Hennekens takes his place among distinguished honorees that include former Surgeon General of the United States (U.S.), C. Everett Koop, M.D. and former Director of the CDC, William Foege, M.D.
“I am humbled and honored to receive this extraordinary award from the Fries Foundation,” said Hennekens. “This award is especially meaningful to me as my chief motivation to pursue an academic career in preventive cardiovascular medicine was the premature death of my beloved father from sudden cardiac death when I was 17.   I am inspired by Jim and Sara Fries for their commitment to reducing premature death and suffering in the U.S. and worldwide.  To paraphrase my mentor, colleague, and friend, Professor Sir Richard Doll, ‘death is inevitable, but premature death is not’.”
Hennekens has conducted seminal research on aspirin, statins, angiotensin converting enzyme inhibitors, and beta adrenergic blockers, all drugs of lifesaving benefit in the treatment and prevention of heart attacks and stroke.   He was the founding principal investigator (PI) of the landmark Physician's Health Study of 22,071 dedicated and conscientious physicians. Hennekens was also a randomized subject in the trial and took a placebo for five years when his investigator-initiated research grant funded by the U.S. National Institutes of Health was terminated early by the independent and external Data and Safety Monitoring Board due principally to the emergence of a statistically extreme and clinically important reduction in a first heart attack among those assigned at random to aspirin.  He credits the dedicated and conscientious efforts of the participating physicians in enabling him to be the first researcher in the world to discover that aspirin prevents a first heart attack.
He was also the first to demonstrate that aspirin prevents heart attacks, strokes, and cardiovascular deaths when given within 24 hours after onset of symptoms of a heart attack as well as to a wide variety of patients who have survived an event associated with a blockage in the heart, brain, or legs
“I can’t think of a more deserving recipient to receive the Fries Prize for Improving Health than my colleague and friend Charlie Hennekens,” said David J. Bjorkman, M.D., M.S.P.H., dean and executive director of medical affairs in FAU’s Charles E. Schmidt College of Medicine. “Charlie has extraordinary competence, compassion and character and this important award is a fitting acknowledgment of his incredible major and varied contributions to improving the health of people in the U.S. and throughout the world.”   
Bjorkman’s nomination of Hennekens was supported by Marc A. Pfeffer M.D., Ph.D., Dzau Professor of Medicine at Harvard Medical School and David E. DeMets, Ph.D., Halperin Professor of Biostatistics and Informatics at the University of Wisconsin School of Medicine and Public Health.
 Hennekens is a major advocate of a healthy lifestyle. He strongly advises the general public that cardiovascular drugs of lifesaving benefit should be adjuncts not alternatives to therapeutic lifestyle changes. Specifically, the major therapeutic lifestyle changes he advocates include avoidance and cessation of smoking, avoidance and treatment of obesity, and regular physical activity, which could be as minimal as taking brisk 20 minute daily walks, which can be continued even among the elderly.  He also supports the CDC initiative to prevent heart attacks through a multifactorial approach including aspirin, blood pressure control, and cholesterol reduction.
Hennekens is the author of more than 819 peer-reviewed publications, including 617 original reports, 199 reviews/book chapters and three textbooks.  From 1995 to 2005, Science Watch ranked him as the third most widely cited medical researcher in the world and five of the top 20 were his former trainees and/or fellows.  In 2012, Science Heroes ranked Hennekens No. 81 in the history of the world for having saved more than 1.1 million lives. This ranks him ahead of Jonas Salk, who developed the polio vaccine, at number 83 and Henry Heimlich, who invented the Heimlich maneuver, at number 103.


About Charles Hennekens- Currently serving as the  first Sir Richard Doll Research Professor at the Charles E. Schmidt College of Medicine at Florida Atlantic University in Boca Raton, Florida, where he resides. He is also Voluntary Professor of Family and Community Medicine at the University of Miami Miller School of Medicine and Meharry Medical College, Clinical Professor of Preventive Medicine at Nova Southeastern University, and  Visiting Fellow at Green College and the Clinical Trial Service and Epidemiology Studies Unit (CTSU) at the University of Oxford in the United Kingdom where he spent a year studying with Sir Richard Doll and  Sir Richard Peto while funded by a Research Career Development Award from the US NIH. He is also Chair or a member of numerous independent Data and Safety Monitoring Boards for large-scale randomized trials. Can be found on a variety of Social Media sites including Facebook, YouTube, Pinterest and Twitter by searching Charles Hennekens.

About Florida Atlantic University-
Florida Atlantic University, established in 1961, officially opened its doors in 1964 as the fifth public university in Florida. Today, the University serves more than 29,000 undergraduate and graduate students on seven campuses and sites. FAU’s world-class teaching and research faculty serves students through 10 colleges: the Dorothy F. Schmidt College of Arts and Letters, the College of Business, the College for Design and Social Inquiry, the College of Education, the College of Engineering and Computer Science, the Graduate College, the Harriet L. Wilkes Honors College, the Charles E. Schmidt College of Medicine, the Christine E. Lynn College of Nursing and the Charles E. Schmidt College of Science. FAU is ranked as a High Research Activity institution by the Carnegie Foundation for the Advancement of Teaching.

Charles Hennekens
Boca Raton, FL 33431
Charles E Schmidt College of Medicine
Florida Atlantic University
Harvard University
 

Saturday, September 7, 2013

Charles E. Schmidt College of Medicine Professors Warn of the Dangers of Low Blood Sugar Among Diabetics



BOCA RATON,Fla. (August 1, 2013) —Charles H.  Hennekens, M.D., Dr.P.H., the first Sir Richard Doll professor and senior academic adviser to the dean and John Newcomer MD, Vice Dean for Research and Graduate Programs in the Charles E. Schmidt College of Medicine at Florida Atlantic University published in this month’s American Journal of Medicine a warning to clinicians and their patients about the dangers of low blood sugar among diabetics.
 Hennekens and Newcomer state that “based on the totality of evidence, the serious and life threatening risks of low blood sugar in diabetes are definite.”  They also note that prior concerns about higher death rates in diabetes who attempt adequate control of their blood sugar are premature and unwarranted.
 Hennekens and Newcomer are major advocates of a healthy lifestyle. He strongly advises the general public that cardiovascular drugs of lifesaving benefit should be adjuncts not alternatives to therapeutic lifestyle changes. Specifically, the major therapeutic lifestyle changes they advocate include avoidance and cessation of smoking, avoidance and treatment of obesity, and regular physical activity which could be as minimal as taking brisk 20 minute daily walks, which can be continued even among the elderly.  
Hennekens is the author of more than 819 peer-reviewed publications, including 617 original reports, 199 reviews/book chapters and three textbooks.  From 1995 to 2005, Science Watch ranked him as the third most widely cited medical researcher in the world and five of the top 20 were his former trainees and/or fellows.  In 2012, Science Heroes ranked Hennekens No. 81 in the history of the world for having saved more than 1.1 million lives.   This ranks him ahead of Jonas Salk, who developed the polio vaccine, at number 83 and Henry Heimlich, who invented the Heimlich maneuver, at number 103.
           Newcomer joined the faculty of Washington University School of Medicine in St. Louis in 1990. Over his 20 years there, he became the Gregory B. Couch Professor of Psychiatry, Psychology and Medicine, Medical Director of the Center for Clinical Studies, as well as Director of Regulatory Support and Co-Director of the Center for Applied Research Science within the NIH-funded Institute of Clinical and Translational Sciences. At the Leonard M. Miller School of Medicine at the University of Miami from 2011-2012, he served as Senior Associate Dean for Clinical Research and Leonard M. Miller Professor of Psychiatry and Behavioral Sciences. He has received a number of honors and awards, including an Exemplary Psychiatrist Award from the National Alliance for the Mentally Ill (NAMI), an Independent Scientist Award from the National Institute of Mental Health (NIMH) and a Gerald L. Klerman Award for Outstanding Clinical Research from the National Alliance for research on Schizophrenia and Depression (NARSAD). 



About Charles Hennekens- Currently serving as the  first Sir Richard Doll Research Professor at the Charles E. Schmidt College of Medicine at Florida Atlantic University in Boca Raton, Florida, where he resides. He is also Voluntary Professor of Family and Community Medicine at the University of Miami Miller School of Medicine and Meharry Medical College, Clinical Professor of Preventive Medicine at Nova Southeastern University, and  Visiting Fellow at Green College and the Clinical Trial Service and Epidemiology Studies Unit (CTSU) at the University of Oxford in the United Kingdom where he spent a year studying with Sir Richard Doll and  Sir Richard Peto while funded by a Research Career Development Award from the US NIH. He is also Chair or a member of numerous independent Data and Safety Monitoring Boards for large-scale randomized trials. Can be found on a variety of Social Media sites including Facebook, YouTube, Pinterest and Twitter by searching Charles Hennekens.




About Florida Atlantic University- Florida Atlantic University, established in 1961, officially opened its doors in 1964 as the fifth public university in Florida. Today, the University serves more than 29,000 undergraduate and graduate students on seven campuses and sites. FAU’s world-class teaching and research faculty serves students through 10 colleges: the Dorothy F. Schmidt College of Arts and Letters, the College of Business, the College for Design and Social Inquiry, the College of Education, the College of Engineering and Computer Science, the Graduate College, the Harriet L. Wilkes Honors College, the Charles E. Schmidt College of Medicine, the Christine E. Lynn College of Nursing and the Charles E. Schmidt College of Science. FAU is ranked as a High Research Activity institution by the Carnegie Foundation for the Advancement of Teaching.



Charles Hennekens 
Boca Raton, FL 33431
Charles E Schmidt College of Medicine
Florida Atlantic University
Harvard University
 


Wednesday, July 17, 2013

Charles Hennekens collaborates on most comprehensive analyses of NSAIDs and coxibs

Jul. 17, 2013 - BOCA RATON, Fla. -- Charles H. Hennekens, MD, DrPH, the first Sir Richard Doll professor and senior academic advisor to the dean in the Charles E. Schmidt College of Medicine at Florida Atlantic University has published in the current issue of the Lancet the most comprehensive analyses of the benefits and risks of non-steroidal anti-inflammatory drugs (NSAIDs), which include cyclo-oxygenase-
2 inhibitors (coxibs).

Hennekens and colleagues from around the world, under the direction of the Clinical Trial Service and Epidemiology Studies Unit at the University of Oxford, conducted a world-wide meta-analyses using individual participant data from 280 trials of NSAIDs vs. placebo and 474 trials of NSAID vs. another NSAID, which involved a total of 353,809 participants and a total of 233,798 person-years. These results address risks and benefits of drugs used for relief of inflammatory arthritis including cardiovascular disease and other relevant outcomes such as gastrointestinal effects.

"The vascular risks of high-dose diclofenac and ibuprofen are comparable to coxibs, while high-dose naproxen is associated with less vascular risk than other NSAIDs," said Hennekens. "Although NSAIDs increase vascular and gastrointestinal risks, their magnitude can be predicted, which may help guide clinical decision-making."

David J. Bjorkman, MD, MSPH, dean of the Charles E. Schmidt College of Medicine at FAU and a gastroenterologist noted that "these are the most comprehensive analyses ever conducted of the benefits and risks of NSAIDs, which include coxibs, and should help guide healthcare providers in their prescribing patterns."

Hennekens concluded that "from a clinical and policy perspective, the available data suggest that for relief of pain of inflammatory arthritis, naproxen may have the best benefit-to-risk ratio on cardiovascular disease (CVD). In contrast to naproxen, other traditional NSAIDS and coxibs confer similar moderately increased risks of CVD. At present, individual clinical judgments about coxibs and nonselective NSAIDs should not be limited to risks of CVD. They should also include concerns about non-CVD risks, such as gastrointestinal bleeding and other benefits, including improved quality of life resulting from decreases in impairment from musculoskeletal pain syndromes."

Science Watch ranked Hennekens as the third most widely cited medical researcher in the world from 1995-2005, and five of the top 20 were his former trainees and/or fellows. In addition, in 2012 Science Heroes, ranked Hennekens No. 81 in the history of the world for having saved more than 1.1 million lives.

About Charles Hennekens-Currently serving as the  first Sir Richard Doll Research Professor at the Charles E. Schmidt College of Medicine at Florida Atlantic University in Boca Raton, Florida, where he resides. He is also Voluntary Professor of Family and Community Medicine at the University of Miami Miller School of Medicine and Meharry Medical College, Clinical Professor of Preventive Medicine at Nova Southeastern University, and  Visiting Fellow at Green College and the Clinical Trial Service and Epidemiology Studies Unit (CTSU) at the University of Oxford in the United Kingdom where he spent a year studying with Sir Richard Doll and  Sir Richard Peto while funded by a Research Career Development Award from the US NIH. He is also Chair or a member of numerous independent Data and Safety Monitoring Boards for large-scale randomized trials. Can be found on a variety of Social Media sites including Facebook, YouTube, Pinterest and Twitter by searching Charles Hennekens.

About Florida Atlantic University-Florida Atlantic University, established in 1961, officially opened its doors in 1964 as the fifth public university in Florida. Today, the University, with an annual economic impact of $6.3 billion, serves more than 30,000 undergraduate and graduate students at sites throughout its six-county service region in southeast Florida. FAU's world-class teaching and research faculty serves students through 10 colleges: the Dorothy F. Schmidt College of Arts and Letters, the College of Business, the College for Design and Social Inquiry, the College of Education, the College of Engineering and Computer Science, the Graduate College, the Harriet L. Wilkes Honors College, the Charles E. Schmidt College of Medicine, the Christine E. Lynn College of Nursing and the Charles E. Schmidt College of Science. FAU is ranked as a High Research Activity institution by the Carnegie Foundation for the Advancement of Teaching. The University is placing special focus on the rapid development of three signature themes – marine and coastal issues, biotechnology and contemporary societal challenges – which provide opportunities for faculty and students to build upon FAU's existing strengths in research and scholarship.
 

Friday, July 12, 2013

Charles Hennekens Representative Peer Review Publications

Representative Peer Review Publications

Dr. Hennekens is the author/co-author of 805 publications including 591 original reports, 211 reviews and book chapters, and 3 textbooks. Here we show only since year 2004.
  • Williams A, Hennekens CH. The role of aspirin in cardiovascular diseases: Forgotten benefits. Expert Opin Pharmacother 2004; 5:109-115.
  • Hennekens CH. The ALLHAT-LLT and ASCOT-LLA trials: Are the discrepancies more apparent than real? Cur Ather Rep, 2004; 6:9-12.
  • Hennekens, CH. Aspirin: the need for wider utilization in the treatment and prevention of cardiovascular disease in patients with rheumatoid arthritis. In: Gastric Protection in NSAID Therapy. Red Bank, NJ: Fallon Medica; 2004.
  • Hussein, SA, Hennekens CH, Lamas GA. An update on clinical trials in pacing: Is dual chamber pacing better? Curr Opin Cardiol. 2004 Jan;19(1):12-8.
  • Casey DE, Haupt DW, Newcomer JW, Henderson DC, Sernyak MJ, Davidson M, Lindenmayer JP, Manoukian SV, Banerji MA, Lebovitz HE, Hennekens CH. Anti-psychotic drug associated weight gain and metabolic abnormalities: implications for increased mortality from schizophrenia. J Clin Psych, 2004; 65 Suppl 7:4-18.
  • Splaver A, Lamas GA, Hennekens CH. Homocysteine and cardiovascular disease: biological mechanisms, observational epidemiology and the need for randomized trials. Am Heart J, 2004; 148(1):34-40.
  • Shields M, Hennekens CH. Management of metabolic syndrome: aspirin. In Grundy S (Ed), Endocrinol Metab Clin N Am. 2004; 33:577-93.
  • Novela C, Hennekens CH. Hypothesis: Atorvastatin has unique pleiotropic effects leading to early clinical benefits. J Cardiovasc Pharm & Ther, 2004; 9(1): 61-63.
  • Hennekens CH, Kanatterud G, Pfeffer M. Aspirin therapy for diabetes mellitus: clinical and research challenges. Diabetes Care, 2004;27(11):2752-4.
  • Hennekens CH, Schror K, Weisman S, FitzGerald G. Terms and conditions: semantic complexity and aspirin resistance. Circ, 2004; 110:1706-1708.
  • Hennekens CH, Hollar D, Agatston AS. Aspirin and statins to decrease risks of cardiovascular disease: The need for wider utilization. Business Briefing: US Cardiology, 2004:43-44.
  • Kurth T, Henneknes CH, Buring JE, Gaziano JM. Apsirin, NSAIDs, and COS-2 inhibitors in cardiovascular disease: possible interactions and implications for treatment of rheumatoid arthritis. Curr Rheum Rpts, 2004;6(5):351-366.
  • Pocock S, Wang D, Wilhelmson L, Hennekens CH. The data monitoring experience in CHARM. In: Friedman L, Furberg C, and DeMets D. Data Monitoring in Clinical Trials. 2005, Case11:166-179, Springer, NY
  • DeMets D, Hennekens CH. The Physicians Health Study: Issues in the Early Termination of the Aspirin Component. In: Friedman L, Furberg C, and DeMets D. Data Monitoring. In Clinical Trials: A Case Studies Approach. 2005, Case3:73-85, Springer,NY .
  • Hollar, D Hennekens CH. Antioxidant vitamins and cardiovascular disease: Randomized trials fail to fulfill the promises of observational epidemiology. In: Tardiff JC, Bourassa MG (eds). Antioxidants and Cardiovascular Disease. Dordrecht, The Netherlands: Kluwer Academic Publishers, 2005; 305-327, Springer, NY
  • Levine RS, Briggs NC, Hussani DA, Hennekens CH. Health disparities by race: geographic studies of black:white and other racial differences. Chapter 29 in Satcher D and Pamies R (Eds). Multicultural Medicine and Health Disparity, 2005, McGraw-Hill,NY.
  • Stier B, Hennekens CH. Phenylpropanolomine and hemorrhagic stroke in the Hemorrhagic Stroke Project: A reappraisal in the context of science, the Food and Drug Administration, and the law. Ann Epidemiol, 2005;16:49-52.
  • Hennekens CH, Hennekens A, Hollar, D, Casey DE. Schizophrenia and increased risk of cardiovascular disease. AHJ, 2005;150:1115-1121.
  • Bowman TS, Hennekens, CH. Cigarette Smoking and Cessation. In: Gaziano JM (ed). Atlas of Cardiovascular Risk Factors. (first edition). Philadelphia, PA: Current Medicine, 2005,
  • Cryer B, Hennekens CH, Hochberg M, Katz PO Changing the Patterns of Coxibs andNSAIDs Prescribing: Balancing CV and GI Risks. Medscape Clinical Update February 17, 2006. Available at: http//www.medscape.com/viewprogram/5060
  • Williams RA, Gavin JR, Phillips RA, Sumner AE, Duncan AK, Hollar D, Hennekens CH. High-risk African-Americans with multiple risk factors: Challenges in prevention, diagnosis, and treatment. Ethnicity and Disease, 2006;16:633-639.
  • Gorelick P, Sechenova O, Hennekens CH: Evolving perspectives on clopidogrel in the treatment of ischemic stroke. JCPT, 2006;4:245-248
  • Serebruany V, Hennekens CH: Hypothesis: Antiplatelet effects of selective serotonin reuptake inhibitors cause clinical benefits on cardiovascular disease and increase risks of bleeding. J Cardiovasc Pharm & Thera, 2006;10:63-64.
  • Hennekens CH, Kowalczykowski M, Hollar D: Lack of deleterious interaction between angiotensin receptor blockers and beta-blockers in the treatment of patients with heart failure JCPT, 2006;2:1-3
  • Hennekens CH, Hollar D, Eidelman RS, Agatston AS. Recent randomized clinical trials of statins and the revised National Cholesterol Education Guidelines: Implications for Primary Healthcare Providers. MedGenMed, 2006; 8:54-56.
  • Hennekens, CH, Sechenova O, Hollar D, Serebruany V: Dose of aspirin in the treatment and prevention of cardiovascular disease; current and future directions. J Cardiovasc Pharm and Ther. 2006, 11(3):1-7.
  • Williams RA, Flack J, Gavin J, Schneider W, Hennekens CH: Guidelines for the Management of High Risk African-Americans with Multiple Cardiovascular Risk Factors: Recommendations from an Expert Consensus Panel, Ethnicity and Disease, 2007;17:210-217.
  • Gao R, Hennekens CH. Treatment and Prevention of Cardiovascular Disease: The need for wider and appropriate utilization of aspirin in China. Chinese Journal of Internal Medicine 2007;27:78-81
  • Hennekens CH; Aspirin in the Secondary and Primary Prevention of Cardiovascular Disease in Medicina Clinica: Aspirin and cardiovascular disease in the XXI Century. Bueno H (ed), 2007, in press.
  • Hennekens CH: Clinical Benefiits of Aspirin and Statins on Cardiovascular Disease Individually and In Combination , in Libby P (ed) Proceedings of the Inflammation, Atherosclerosis and Aspirin Summit Meeting, 2007, Inflammation, Atherosclerosis, and Aspirin: New Insights, Libby P., Knappertz V (eds)
  • Carillo-Jimenez R,Borzak S, Sechenova O, Hennekens CH: Brain Naturiuretic Peptide: Clinical and Research Challenges JCPT, 2007, in press
  • Hennekens CH, Schneider W, Barice EJ: Childhood Obesity: General Considerations, Ped Res, 2007, 61(6):634-635.
  • Hennekens CH: Aspirin in the treatment and prevention of cardiovascular disease: current perspectives and future directions. Current Athero Reports, 2007, 9(5):409-416.
  • Hennekens CH: Combined pravastatin and acetylsalicylic acid therapy: additive benefits in the management of coronary patients. Am J Cardiovasc Drugs, 2007, 7: 9-11.
  • Hennekens CH: Metabolic Syndrome as a co-morbidity in schizophrenia, CMAJ, 2008, in press
  • Kilbourne B, Hennekens CH: African-Americans and Coronary Heart Disease: Psychosocial comorbidities in The African-American Handbook of Health, 2008, in press.
  • Serebruany V, Malinin A, Hennekens CH: Statins may increase the risk of hemorrhagic stroke. Cerebrovasc. Dis 2007.24:477-479.
  • Newcomer JW, Hennekens CH: Major mental illness and premature morbidity and mortality from cardiovascular disease: the need for new paradigms, JAMA, 2007, 298:1794-1796.
  • Levine RS, Briggs NC, Hollar D, Husaini BA, Hennekens CH, Kilbourne BJ. Descriptive and analytic epidemiologic studies to identify modifiable determinants of disparities in mortality rates between Blacks and Whites. Ethnicity and Disease, 2007 Spring;17(2):280-3.
  • Hennekens CH: Fixed-dose drug combinations of statins: Strengths, limitations, general and specific regulatory considerations. Am J Cardiovasc Drugs, 2008, 8:155-160.
  • Hennekens CH, Borzak S: Cyclooxygenase 2 Inhibitors and most traditional nonsteroidal anti-inflammatory drugs produce similar moderately increased risks of cardiovascular disease; JCPT, 2008 Mar; 13(1):41-50.
  • Fleischacker WW, Cetkovic-Bakmas M, DeHert M, Hennekens CH, Lambert M, Leucht S, Maj M, McIntyre RS, Naber D, Newcomer J, Olfson M, Osby U, Sartorius N, Lieberman J: Medical comorbidities in patients with severe mental illness: Clinical, policy and research challenges, J Clin Psych, 2008, in press
  • Hennekens CH, Schneider WR: Statins and Aspirin Produce Additive Benefits in the Treatment of Cardiovascular Disease, Expert Review of Cardiovascular Therapy, 2008, 6(1): 95-107.
  • Hennekens CH: Foreword to The Great American Heart Hoax. Ozner M. Benbella Books, Dallas Texas, 2008
  • MacIntyre A, Ehrenkranz NJ, Hennekens CH: Reducing infectious disease complications of healthcare practices: the need for medical student education. NEJM, 2008, submitted
  • Hennekens CH, DeMets D, Bairey-Merz CN, Borzak S, Borer J: Doing more good than harm: the need for a cease fire. AJM, 2009, in press.
  • Hennekens CH: Statin inducted muscle symptoms and signs: an hypothesis to reconcile randomized evidence with clinical impressions AJM, 2009, in press


Charles Hennekens
Boca Raton, FL 33431
Charles E Schmidt College of Medicine
Florida Atlantic University
Harvard University

Monday, June 10, 2013

Charles Hennekens Named Senior Academic Advisor to the Dean at Charles E. Schmidt College of Medicine



Florida Atlantic University’s Charles E. Schmidt College of Medicine welcomed Dr. John W. Newcomer, M.D., as vice dean for research and graduate programs, and Dr. Charles H. Hennekens, M.D., Dr.P.H., the first Sir Richard Doll Professor in FAU’s Charles E. Schmidt College of Medicine, as senior academic advisor to the dean.

“We are very pleased to welcome Dr. Newcomer to the Charles E. Schmidt College of Medicine,” said Dr. David J. Bjorkman, M.D., M.S.P.H., dean of FAU’s Charles E. Schmidt College of Medicine. “Working with Dr. Hennekens and other members of our leadership team, Dr. Newcomer will bring a wealth of experience and a proven track record that is a tremendous asset for the growth and success of our new medical school and the expansion of our research programs to achieve the vision of our president.”

Newcomer has been a principal investigator (PI) on research grants funded through the National Institutes of Health (NIH) for the past 20 years. He has held research leadership positions at Washington University in St. Louis where he was also a faculty member in the School of Medicine for more than 20 years, and at the University of Miami. In his current role, Newcomer will provide leadership in areas that include research infrastructure development and support, faculty development, collaboration with biotech industry partners, growth of sponsored research, as well as community outreach and education. He will work closely with the College’s affiliated research organizations, affiliated hospitals and community business partners.

“This is an exciting time of strategic growth for Florida Atlantic University’s new medical school,” said Newcomer. “I look forward to working with my colleagues and our collaborators to advance research initiatives for the College and the University.”

FAU’s Charles E. Schmidt College of Medicine’s research is focused in the areas of
cardiovascular disease and stroke, cancer, neurodegenerative diseases, including Parkinson’s and Alzheimer’s disease, genetic eye diseases, macular degeneration and cataracts, autoimmune diseases, malaria and HIV/AIDS. The College has research affiliations with several leading organizations including Scripps Research Institute, Scripps Florida, Max Planck Florida Institute for Neurosciences, the Torrey Pines Institute for Molecular Studies, and the Vaccine Gene Therapy Institute Florida.

In his new role as senior academic advisor to the dean, Hennekens will work closely with Bjorkman, Newcomer and other College leadership to help advance the new medical school in the areas of faculty development, strategic planning and research program development.
Hennekens is a distinguished researcher, teacher and clinician. He was the leading recipient of investigator-initiated research grants from NIH for many years. From 1995 to 2005, Science Watch ranked Hennekens as the third most widely-cited medical researcher in the world and five of the top 20 were his former trainees and/or fellows. In 2012,Science Heroes ranked Hennekens No. 81 in the history of the world for having saved more than 1.1 million lives. Hennekens has conducted landmark trials on statins, aspirin, angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs). He also is a recipient of numerous honors and awards, which include curriculum design and teaching medical students, as well as students of public health at Harvard, Boston University, University of Miami and other prestigious academic institutions throughout the world.

About Charles Hennekens- Currently serving as the  first Sir Richard Doll Research Professor at the Charles E. Schmidt College of Medicine at Florida Atlantic University in Boca Raton, Florida, where he resides. He is also Voluntary Professor of Family and Community Medicine at the University of Miami Miller School of Medicine and Meharry Medical College, Clinical Professor of Preventive Medicine at Nova Southeastern University, and  Visiting Fellow at Green College and the Clinical Trial Service and Epidemiology Studies Unit (CTSU) at the University of Oxford in the United Kingdom where he spent a year studying with Sir Richard Doll and  Sir Richard Peto while funded by a Research Career Development Award from the US NIH. He is also Chair or a member of numerous independent Data and Safety Monitoring Boards for large-scale randomized trials. Can be found on a variety of Social Media sites including Facebook, YouTube, Pinterest and Twitter by searching Charles Hennekens.

About Florida Atlantic University-
Florida Atlantic University, established in 1961, officially opened its doors in 1964 as the fifth public university in Florida. Today, the University serves more than 29,000 undergraduate and graduate students on seven campuses and sites. FAU’s world-class teaching and research faculty serves students through 10 colleges: the Dorothy F. Schmidt College of Arts and Letters, the College of Business, the College for Design and Social Inquiry, the College of Education, the College of Engineering and Computer Science, the Graduate College, the Harriet L. Wilkes Honors College, the Charles E. Schmidt College of Medicine, the Christine E. Lynn College of Nursing and the Charles E. Schmidt College of Science. FAU is ranked as a High Research Activity institution by the Carnegie Foundation for the Advancement of Teaching.

Charles Hennekens
Boca Raton, FL 33431
Charles E Schmidt College of Medicine
Florida Atlantic University
Harvard University